Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 1
1957 1
1961 2
1964 3
1965 2
1967 1
1969 4
1970 1
1971 6
1972 5
1973 11
1974 10
1975 3
1976 4
1977 2
1978 2
1979 1
1980 2
1982 10
1983 3
1984 7
1985 8
1986 6
1987 4
1988 7
1989 10
1990 5
1991 7
1992 8
1993 10
1994 10
1995 11
1996 9
1997 10
1998 14
1999 17
2000 6
2001 11
2002 7
2003 9
2004 6
2005 9
2006 10
2007 5
2008 8
2009 8
2010 13
2011 10
2012 9
2013 18
2014 10
2015 9
2016 7
2017 9
2018 1
2019 4
2020 2
2021 7
2022 8
2023 10
2024 6
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
Polyamine-iron chelator conjugate.
Bergeron RJ, McManis JS, Franklin AM, Yao H, Weimar WR. Bergeron RJ, et al. J Med Chem. 2003 Dec 4;46(25):5478-83. doi: 10.1021/jm0302694. J Med Chem. 2003. PMID: 14640556
Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Rai SK, et al. Among authors: bergeron r jr. Metabolism. 2020 Sep;110:154297. doi: 10.1016/j.metabol.2020.154297. Epub 2020 Jun 18. Metabolism. 2020. PMID: 32562798 Free PMC article.
The Good and Bad Sides of NAAG.
Khacho P, Wang B, Bergeron R. Khacho P, et al. Among authors: bergeron r. Adv Pharmacol. 2016;76:311-49. doi: 10.1016/bs.apha.2016.01.003. Epub 2016 Mar 2. Adv Pharmacol. 2016. PMID: 27288081 Review.
NAAG, NMDA receptor and psychosis.
Bergeron R, Coyle JT. Bergeron R, et al. Curr Med Chem. 2012;19(9):1360-4. doi: 10.2174/092986712799462685. Curr Med Chem. 2012. PMID: 22304714 Free PMC article. Review.
Polyamine analogue antiarrhythmics.
Bergeron RJ, Wiegand J, Weimar WR, Snyder PS. Bergeron RJ, et al. Pharmacol Res. 1998 Nov;38(5):367-80. doi: 10.1006/phrs.1998.0384. Pharmacol Res. 1998. PMID: 9806817
397 results